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Background: The UVB and heat rekindling (UVB/HR) model shows
potential as a translatable inflammatory pain model. However, the occur-
rence of central sensitization in this model, a fundamental mechanism
underlying chronic pain, has been debated. Face, construct and predictive
validity are key requisites of animal models; electromyogram (EMG)
recordings were utilized to objectively demonstrate validity of the rat
UVB/HR model.
Methods: The UVB/HR model was induced on the heel of the hind paw
under anaesthesia. Mechanical withdrawal thresholds (MWTs) were
obtained from biceps femoris EMG responses to a gradually increasing pinch
at the mid hind paw region under alfaxalone anaesthesia, 96 h after UVB
irradiation. MWT was compared between UVB/HR and SHAM-treated rats
(anaesthetic only). Underlying central mechanisms in the model were
pharmacologically validated by MWT measurement following intrathecal
N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801, or saline.
Results: Secondary hyperalgesia was confirmed by a significantly lower
pre-drug MWT {mean [±standard error of the mean (SEM)]} in UVB/HR
[56.3 (±2.1) g/mm2, n = 15] compared with SHAM-treated rats [69.3
(±2.9) g/mm2, n = 8], confirming face validity of the model. Predictive
validity was demonstrated by the attenuation of secondary hyperalgesia by
MK-801, where mean (±SEM) MWT was significantly higher [77.2
(±5.9) g/mm2 n = 7] in comparison with pre-drug [57.8 (±3.5) g/mm2
n = 7] and saline [57.0 (±3.2) g/mm2 n = 8] at peak drug effect. The
occurrence of central sensitization confirmed construct validity of the
UVB/HR model.
Conclusions: This study used objective outcome measures of secondary
hyperalgesia to validate the rat UVB/HR model as a translational model of
inflammatory pain.
1. Introduction
The pursuit of novel analgesics to adequately treat
chronic pain remains a pressing demand (Ballantyne
et al., 2010), and progression in the development of
mechanistically novel analgesics is remarkably low
(Woolf, 2010). This has been attributed in part to
mechanistic differences between the aetiopathogen-
esis of pain in animal models compared with the
clinical pain conditions in man, highlighting the
importance of translational models of chronic pain
(Pound et al., 2004; Rice et al., 2008; Mogil et al.,
2010).
A pragmatic approach of reverse translating a well-
characterized human experimental pain model
(Hoffmann and Schmelz, 1999; Benrath et al., 2001;
Gustorff et al., 2004, 2013; Bishop et al., 2009) to
animals (Saade et al., 2000, 2008; Davies et al., 2005;
Themistocleous et al., 2006; Bishop et al., 2007) has
been undertaken with an inflammatory pain model
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induced by ultraviolet (UV) irradiation in the UV-B
range (UVB model). The UVB model is well character-
ized as a model of peripheral sensitization, where
primary hyperalgesic responses peak between 24 and
48 h in rats and in humans.
In order for the UVB model to be utilized as a
translational model of inflammatory pain, face, con-
struct and predictive validity must be demonstrated in
the animal model (Rice et al., 2008; Ballantyne et al.,
2010). Therefore central sensitization, a fundamental
underlying mechanism of chronic pain must also be
evoked in the model (Woolf, 2007). Davies et al.
(2011) provided behavioural evidence of central sen-
sitization in the rat UVB model through induction of
secondary hyperalgesia, which was enhanced and pro-
longed by heat rekindling (HR) of the irradiated area
(UVB/HR model). A similar behavioural response is
observed in humans following UVB/HR inflammation
(Cookson et al., 2005), indicative of face validity.
Despite this, central sensitization remains a controver-
sial feature of the model due to conflicting evidence
regarding the occurrence of secondary hyperalgesia
using a similar protocol (Bishop et al., 2010). These
differing results may be attributed to the use of behav-
ioural outcome measures to detect secondary hyper-
algesia, which introduces an element of subjectivity
concerning judgment of withdrawal responses (Grigg
et al., 2007). Despite the importance of demonstrating
central sensitization in the UVB/HR model, it must
also be acknowledged that evoking central sensitiza-
tion is not sufficient evidence that the model mimics
chronic pain, as some acute pain states can also recruit
central pain mechanisms. This knowledge is also
lacking for other experimental inflammatory pain
models in animals that utilize algogenic substances
such as carrageenan to induce inflammatory pain.
The current study aimed to demonstrate induction
of central sensitization in the rat UVB/HR model, and
thus present construct validity, using objective biomark-
ers of nociception (Willer, 1985). Biceps femoris
electromyogram (EMG) withdrawal responses were
measured following application of controlled
mechanical pinch to the area of secondary hyperalge-
sia of the hind paw. A lower mechanical withdrawal
threshold (MWT) was predicted in animals exposed to
UVB/HR compared with SHAM-treated rats. MK-801,
an N-methyl-D-aspartate (NMDA) receptor antago-
nist, was intrathecally (i.t.) administered to attenuate
central sensitization. It was hypothesized MK-801
would increase the MWT to pinch in the area of sec-
ondary hyperalgesia in UVB/HR rats. This study pro-
vided evidence of central sensitization in the UVB/HR
model through the induction of secondary hyperalge-
sia that was attenuated by intrathecal MK-801.
2. Materials and methods
2.1 Animals
All experiments were performed on adult male Wistar rats
(weighing between 250 and 300 g; Harlan, Derby, UK) in
accordance with the new European Union Directive and its
predecessor the Animals Scientific Procedures Act. Rats were
housed in groups of four in laboratory cages (480 × 375 ×
210 mm) containing sawdust and ad libitum access to labora-
tory chow and water. Cages were enriched with a cylindrical
tube. Ambient temperature was maintained between 19 and
23 °C. Animals were randomly divided into three treatment
groups by randomly drawing coloured markers (three
colours) from a container, with each colour representing a
particular group (n = 8 per group, as determined from a power
calculation using data derived from Davies et al., 2011, with
an alpha value of 5% and beta value of 80%; Researcher’s
Toolkit, sample size calculator; Decision Support Systems,
Fort Worth, TX, USA): SHAM treatment (anaesthetic
only) + MK-801, UVB/HR + saline, UVB/HR + MK-801.
The UVB/HR model was induced using similar methodol-
ogy to that of Davies et al. (2011) and described briefly below.
2.2 UVB irradiation
Animals were anaesthetized with a single intraperitoneal
dose of sodium pentobarbital (pentobarbital sodium salt C-II;
Sigma, St. Louis, MO, USA) (45 mg/kg) and were positioned
in a UV chamber parallel to a UVB light source (TL01 tubes;
Philips, Guildford, UK; kmax = 314 nm). UVB irradiation
(290–320 nm wavelength) at a dose of 1000 mJ/cm2 was
confined to the heel area of the right hind paw of the rat,
with the remaining right hind paw shielded from exposure
What’s already known about this topic?
• Most current animal chronic pain models lack
translatability to human subjects.
• Primary hyperalgesia is an established feature of
the UVB/heat rekindling inflammatory pain
model in rodents and humans, but the presence
of secondary hyperalgesia, a hallmark feature of
central sensitization and thus chronic pain, is
contentious.
What does this study add?
• Secondary hyperalgesia was demonstrated in the
rat UVB/heat rekindling model using an objec-
tive outcome measure (electromyogram), over-
coming the subjective limitations of previous
behavioural studies.
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with black tape and the body with black cloth. The UVB
source was calibrated prior to experiments using an irradia-
tion probe placed at an equivalent distance from the light
tubes as the animals’ hind paw and the length of time
needed to deliver an integrated dose of 1000 mJ/cm2 was
determined. Rats in the SHAM treatment group were anaes-
thetized but not exposed to UVB.
2.3 Heat rekindling
HR was carried out 24 h after UVB treatment. Anaesthesia
was induced as detailed above, and the previously irradiated
heel area was heated at 45 °C using a feedback-controlled
thermode (built in house) held firmly to the skin for a
duration of 5 min. Rats in the SHAM treatment group were
anaesthetized but did not receive HR treatment.
2.4 EMG recording
EMG experiments took place 4 days after initial UVB
treatment.
2.4.1 Surgical preparation
Animals were anaesthetized with halothane delivered by a
face mask to allow cannulation of the jugular vein. Once
venous access had been established, halothane administra-
tion was discontinued and anaesthesia maintained with a
continuous intravenous infusion of alfaxalone (Alfaxan;
Malvern Link, UK) at approximately 40 mg/kg/h titrated to
maintain an adequate depth of anaesthesia for the experi-
mental procedures. Depth of anaesthesia was monitored
using a combination of clinical signs and respiratory rate. The
trachea was cannulated to keep the airways patent and facili-
tate spontaneous respiration. A rectal probe was used to
monitor body temperature, linked to a feedback-controlled
thermal blanket to maintain body temperature between 37
and 38 °C.
Pharmacological agents were delivered i.t. via an implanted
guide needle. For placement of the intrathecal guide needle,
the rat was arched over a small beaker (placed beneath the
pelvis) to aid visualization and to optimize the space between
spinous processes in the lower lumbar region. The interspace
between lumbar region L5 and L6 was determined to be an
accessible region where hind paw afferents enter the spinal
column and were identified as being roughly above the pro-
trusion of the iliac crest. The stylet of a 22-gauge spinal needle
was inserted into the space between the processes until a tail
flick was elicited. A larger 21-gauge needle was then threaded
over the stylet and secured in place using superglue. The stylet
was left in place until time of injection in order to avoid
obstruction of the lumen of the needle.
EMG responses in the biceps femoris to noxious stimula-
tion of the right hind paw were used as an outcome measure
of nociceptor activity. Muscle activity was recorded from two
Teflon (Advent Research Materials, Oxford, UK)-coated stain-
less steel wires (approximately 10 cm) that were stripped to
expose 2–3 mm of steel and threaded through a 25-gauge
needle, with the stripped end bent over the tip to form a hook.
The biceps femoris was pinched to make the muscle taut and
the needle inserted 3–5 mm into the muscle belly. The needle
was withdrawn slowly to allow the wire to remain embedded
in the muscle. The second wire was placed around 1 cm from
the first. A grounding earth wire was attached to a 25-gauge
needle by a crocodile clip and inserted subcutaneously
towards the neck of the rat. The signal across the wire elec-
trode pair was amplified (×2000, NeuroLog preamplifier; Digi-
timer, Letchworth Garden City, UK), filtered (bandwidth
50 Hz to 5 kHz) and displayed on an oscilloscope (LeCroy
9304A, Quad 200 MHz oscilloscope; LeCroy, Chestnut Ridge,
NY, USA). EMG was simultaneously captured at 5–10 kHz on
a personal computer running Cambridge Electronic Design
(CED) Spike 2 version 5.13, via a CED 1401plus [Cambridge
Electronic Design (CED), Cambridge, UK].
At the end of the surgical preparation phase, the infusion
rate of alfaxalone was reduced to 36 mg/kg/h and the plane
of anaesthesia allowed to stabilize for an hour before EMG
recording began. If no EMG response was detected in
response to mechanical pinch up to 120 g/mm2, the anaes-
thetic infusion rate was further lowered and allowed to sta-
bilize. The final infusion rate of alfaxalone ranged between
23 and 36 mg/kg/h for all experiments and varied randomly
within group.
2.4.2 Recording EMG response to a ramped
mechanical stimulus
Mechanical withdrawal threshold (MWT) to a noxious
mechanical stimulus applied to the right hind paw, adjacent
to the UVB/HR area (and equivalent area in SHAM-
treated rats) was recorded before and after drug adminis-
tration to investigate the presence of secondary mechanical
hyperalgesia.
A pinch of gradually increasing magnitude was delivered
via a manually controlled pincher (built in house) to the mid
region of the hind paw, between the footpads, until a biceps
femoris EMG response was detected. A steady rate of appli-
cation of the pinch was achieved by following a ramped
guide trace with a rate of increase in pressure of 12 g/mm2/s.
A number of different rates were trialled with 12 g/mm2
found to be an achievable and easily repeatable pinch that
allowed not only precise measurement of MWT, but could
also be discontinued quickly after an EMG response was
detected, to avoid sensitization. MWT (g/mm2) was calcu-
lated on computer program Spike 2 version 5.13. The rate of
application of the mechanical stimulus was kept constant to
limit variability in withdrawal threshold, and the criteria for
determining the EMG withdrawal threshold were standard-
ized as being more than two standard deviation (SD) over
background electrical activity of the muscle. An inter-
stimulus interval of 15 min was maintained to avoid sensi-
tization (Reeh et al., 1987; Carstens and Ansley, 1993). The
pre-drug MWT (g/mm2) was calculated by averaging three
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consecutive pinches with a MWT range within 12.3 g/mm2,
chosen from preliminary data (data not shown) as being one
SD of pre-drug MWT in SHAM-treated rats (n = 5).
2.4.3 Drug treatment
Once a pre-drug MWT was established, either saline (10 μL)
or MK-801 (10 μg in 10 μL of saline) (Ascent Scientific,
Cambridge, UK) was administered i.t. using a 25-μL fixed
needle syringe (SGE Analytical Science, Victoria, Australia)
and delivered via the previously placed guide needle (the
stylet removed prior to administration). The dose of MK-801
used has previously been shown to attenuate central sensiti-
zation in other inflammatory models of pain, with no associ-
ated deficits in motor reflexes (Hama et al., 2003). Post-drug
MWT was analysed every 15 min over a 60-min time course.
Prior to termination of the experiment, correct intrathecal
placement of the needle was verified by monitoring the
efficacy of intrathecal local anaesthetic (20 μL of 0.5% xylo-
caine; 0.5%, Astra Pharmaceuticals, Ltd., Kings Langley, UK)
in abolishing the EMG withdrawal response to noxious pinch.
2.5 Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 5.03 (GraphPad Software, La Jolla, CA, USA). A
one-way analysis of variance (ANOVA) followed by a Bon-
ferroni multiple comparison post hoc test was used to assess
differences between pre-drug MWT of all three groups. The
absence of a significant difference between both of the
UVB/HR treatment groups then allowed a pooling of
UVB/HR pre-drug MWT values. A D’Agostino and Pearson
omnibus normality test was performed, which established
that the pooled UVB/HR data were normally distributed. An
unpaired t-test compared whether pre-drug MWT signifi-
cantly differed between the combined UVB/HR-treated rats
and SHAM treatment. For post-drug analysis, pre-drug
values were not pooled and a D’Agostino and Pearson
omnibus normality test confirmed all groups were normally
distributed. A two-way mixed-model ANOVA followed by
Bonferroni post hoc test compared pre- and post-drug MWT
within each group in a repeated measure design, and MWT
between groups at various time points. Statistical signifi-
cance was defined as p < 0.05.
3. Results
Rats received either UVB/HR or SHAM treatment
(anaesthetic only) to the heel area of the right hind
paw. Intrathecal saline or MK-801 was administered 4
days post-UVB treatment, where n = 8 per group:
UV/HR + MK801, UVB/HR + saline, SHAM + MK-
801.
3.1 UVB/HR causes secondary mechanical
hyperalgesia
One rat in the UVB/HR (+MK-801) group had a pre-
drug MWT greater than two SD above mean pre-drug
MWT of all UVB/HR rats and was thus excluded from
further analysis.
Mean [±standard error of the mean (SEM)] MWT
was significantly lower (by 23%) in the area of sec-
ondary hyperalgesia for rats that received UVB/HR
treatment [56.3 (±2.1) g/mm2, n = 15] compared with
SHAM-treated rats [69.3 (±2.9) g/mm2 n = 8
p = 0.0015] (unpaired t-test, Fig. 1).
3.2 Secondary mechanical hyperalgesia in the
UVB/HR model can be attenuated by MK-801
Centrally acting MK-801 increased MWT in UVB/HR
rats in the area of secondary hyperalgesia, with a peak
Figure 1 Figures showing pre-drug mechani-
cal withdrawal threshold (MWT) to a pinch of
increasing magnitude applied to the mid-
region (i.e., area of secondary hyperalgesia) of
the ipsilateral hind paw in UVB and heat
rekindled (UVB/HR) and SHAM-treated rats. An
example of raw data from a pre-drug recording
is demonstrated in (Ai) from a UVB/HR rat and
(Aii) from a SHAM-treated rat. Scale bars corre-
late to both (Ai) and (Aii). (B) Scatter plot
showing overall pre-drug MWT in UVB/HR
(n = 15) and SHAM-treated rats (n = 8). Each
point represents data from an individual animal
4 days after initial UVB treatment or SHAM
treatment. Horizontal lines represent
mean ± standard error of the mean.
**p < 0.01, unpaired t-test.
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effect observed at 30 min post administration
(Fig. 2A).
A two-way mixed-model ANOVA demonstrated a
significant effect of time (p = 0.049) and group
(p = 0.0032) but failed to show a significant interaction
effect. A Bonferroni post hoc test determined a signifi-
cant difference in time compared with pre-drug value
at 30 min post-MK-801 administration in the UVB/HR
group (n = 7). At this time point, MWT significantly
increased by 33% compared with pre-drug MWT
(Fig. 2B), where the mean (±SEM) MWT increased
from 57.8 (±3.5) g/mm2 pre-drug to 77.2 (±5.9) g/mm2
30 min post-MK-801 injection. There was no statistical
difference at any other time point following MK-801
administration compared with pre-drug MWT in
UVB/HR rats. MK-801 did not significantly alter MWT
at any time point in the SHAM group (Fig. 2B), indi-
cating that the modulation of MWT by MK-801 was
due to alterations in the sensitized nociceptive pathway
and not a general deficit in motor function alone. Saline
had no effect on MWT in UVB/HR rats.
A Bonferroni post hoc test established a significant
effect of group between UVB/HR + MK-801 and UVB/
HR + saline (n = 8) at 30 min post-drug administration
[77.2 (±5.9) g/mm2 compared with 57.0 (±3.2) g/
mm2, respectively]. At this time point, mean MWT in
the UVB/HR + MK-801 group was 35% higher than
UVB/HR + saline. At 45 min post-drug, mean MWT in
the SHAM + MK-801 group (n = 8) was significantly
higher (33%) than UVB/HR + saline [75.3 (3.8) g/
mm2 compared with 56.5 (±3.5) g/mm2]. There was
no statistical difference between groups at any other
time point.
4. Discussion
The UVB model is a model of inflammatory pain that
overcomes the translational limitations of some estab-
lished animal inflammatory pain models that cannot
be readily applied to humans. A major component of
construct validity in chronic pain models is the occur-
rence of central sensitization due to its importance as
a key underlying mechanism in clinical chronic pain
states. The occurrence of central sensitization in the
UVB model has been debated in both rats and
humans (Gustorff et al., 2004, 2013; Bishop et al.,
2009, 2010; Andresen et al., 2011; Davies et al.,
2011; Lorenzini et al., 2011, 2012), and the UVB
model has primarily been utilized in human clinical
trials to assess the efficacy of analgesics in modulating
peripheral sensitization.
Davies et al. (2011) reported central sensitization
for the first time in a rodent UVB model, which was
further enhanced and prolonged upon the addition of
HR (a 5-min application at 45 degrees) 24 h later
(UVB/HR model), analogous to the extension of
capsaicin-mediated hyperalgesia following the addi-
tion of HR in men (Dirks et al., 2003). HR has also
been combined with UVB irradiation in human clini-
cal trials where a 45-degree heat stimulus activates
C-fibre nociceptors but can still be tolerated in men
(Cookson et al., 2005; Wang et al., 2005). The
Figure 2 Figures showing the effect of intrath-
ecal administration of N-methyl-D-aspartate
receptor antagonist, MK-801 or saline on
mechanical withdrawal threshold (MWT) in
response to a pinch of increasing magnitude in
the mid-region (i.e., area of secondary hyperal-
gesia) of the ipsilateral hind paw. An example
of raw data from a UVB/HR rat is demonstrated
in (Ai) showing a pre-drug MWT response and
(Aii) MWT 30 min after MK-801 administration
in the same rat. Scale bars correlate to both
(Ai) and (Aii). (B) Time course of drug action in
all groups [UVB/HR + MK-801 = 7 (squares),
UVB/HR + saline =8 (circles), SHAM + MK-
801 = 8 (triangles)] where MK-801 or saline was
administered immediately after obtaining pre-
drug responses. Post-drug responses were
recorded every 15 min for 60 min, where each
data point represents mean ± standard error
of the mean 4 days after initial UVB or SHAM
treatment. **p < 0.01 within group, ##p < 0.01
between groups, two-way analysis of variance
following by Bonferroni post hoc test.
N.S. Weerasinghe et al. Validation of central sensitization in the UVB/HR model
© 2014 The Authors European Journal of Pain published by John Wiley & Sons Ltd on behalf of
European Pain Federation - EFIC®
Eur J Pain 18 (2014) 1199–1206 1203
increased magnitude and duration of secondary hype-
ralgesia in the UVB/HR model may be attributed to
more sustained C-fibre nociceptor activity and there-
fore a more prolonged C-fibre input to the dorsal horn
of the spinal cord compared with UVB exposure alone.
Here we aimed to demonstrate central sensitization
in the UVB/HR model in rats using an objective bio-
marker of secondary hyperalgesia as an alternative to
the behavioural measures used in previous studies
evaluating the UVB model in rats.
4.1 Face validity
Face validity refers to whether the animal models
possess similar characteristic responses to the human
clinical condition. This was demonstrated by the
reduction in MWT in the secondary area of UVB/HR
rats in comparison with the corresponding site in rats
that received SHAM treatment, which mimics behav-
ioural responses reported upon model induction in
humans (Cookson et al., 2005). Using EMG with-
drawal thresholds to illustrate secondary hyperalgesia
overcomes the limitations of evoked behavioural
responses where there is an element of subjectivity in
terms of what is deemed a withdrawal response and
may be a potential source of disparity between the
results from different studies (Bishop et al., 2010;
Davies et al., 2011). However, it could be argued that
using behavioural outcome measures in awake rats
might better incorporate the multi-modal effects of
pain due to engagement of the cerebral cortex.
A preliminary behavioural study established sec-
ondary hyperalgesia peaked at 96 h post-UVB irradia-
tion when the UVB/HR model was induced under
pentobarbital anaesthesia, and was thus the time point
utilized in the current study. In the present study
mechanical pinch rather than other modalities of
noxious sensory stimulation was used to detect
changes in withdrawal threshold due to the clinical
relevance of mechanical secondary hyperalgesia in
chronic pain states (Raja et al., 1984; Lamotte et al.,
1991; Ali et al., 1996) and underlying mechanisms
mainly thought to result from central sensitization
(Lamotte et al., 1991; Treede et al., 1992; Klede et al.,
2003).
4.2 Predictive validity
Predictive validity refers to the ability of an animal
model to predict therapeutic efficacy in human clinical
conditions and was previously demonstrated in the rat
UVB/HR model using behavioural measures through
attenuation of secondary hyperalgesia by systemic, but
not a peripherally restricted topical dose of a non-
steroidal anti-inflammatory drug (Davies et al., 2011).
We also investigated predictive validity using intrath-
ecal administration of a different class of analgesic
drug, a non-competitive NMDA receptor antagonist,
MK-801 (Latremoliere and Woolf, 2009). Antagonism
of NMDA receptors by MK-801 has been shown to
attenuate central sensitization in other inflammatory
(Ren et al., 1992; Chen and Chen, 2000; Hama et al.,
2003) and neuropathic pain models (Davar et al.,
1991; Seltzer et al., 1991), and was therefore predicted
to ameliorate secondary hyperalgesia in the UVB/HR
model. At high doses MK-801 can potentially cause
motor impairments (Hama et al., 2003) that may be
unfavourable in analgesic drug studies that intend to
measure sensory alterations alone. An absence of
motor deficits is imperative in the present study due to
the recording of reflex withdrawal responses. In order
to control for any effects of MK-801 on motor function
in our anesthetized preparation, we incorporated a
SHAM group of rats that only underwent handling
anaesthesia similar to the UVB/HR groups. MK-801
appeared to demonstrate an ‘over anti-hyperalgesic’
or analgesic effect (at 30 and 45 min post-MK-801
administration in the UVB/HR and SHAM groups,
respectively, in comparison with UVB/HR + saline).
However, MK-801 is unlikely to exert a significant
analgesic effect or motor impairment as no change in
MWT is observed in the SHAM group compared with
pre-drug response. Also, the dose of MK-801 was
chosen due to its ability to attenuate hyperalgesia in
the absence of motor deficits (Hama et al., 2003).
However, the study by Hama et al. (2003) was per-
formed in awake behaving rats, and it is possible that
our technique using an anaesthetized preparation is
more sensitive in detecting subtle changes in motor
responses. An alternative explanation may be that the
surgical preparation adds an additional element of
sensitization that is also diminished by MK-801.
However, the most feasible justification for the subtle
variation in results is attributed to the variability in
EMG recordings to assess MWT between animals.
4.3 Construct validity
Construct validity refers to whether the induced pain
condition in the animal model has similar underlying
neurobiological mechanisms to the human clinical
condition and was indicated by the occurrence of
central sensitization, a key underlying mechanism of
chronic pain, in the UVB/HR model. Central sensiti-
zation can be inferred through the lower MWT in
UVB/HR compared with SHAM-treated rats in the
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area of secondary hyperalgesia, which was subse-
quently increased upon administration of the NMDA
receptor antagonist MK-801.
The present study supports the findings of Davies
et al. (2011), who postulated that previous conflicting
results concerning the occurrence of secondary hype-
ralgesia in the rat UVB model may be due to differ-
ences in methodology used to detect secondary
hyperalgesia between different studies.
The current study involved application of a ramped
force to detect MWT, and due to the nature of EMG
recordings, did not allow detection of the 50% with-
drawal response, akin to the study by Bishop et al.
(2010). An alternative reason for the disparity
between our results and the findings of Bishop et al.
(2009) may be the addition of HR to the UVB model,
which increased the magnitude of central sensitization
to allow detection of a change in 100% withdrawal
threshold in the area of secondary hyperalgesia, which
may not be detectable following UVB exposure only.
Furthermore, the use of an anesthetized preparation
compared with awake behaving animals removes con-
scious modulation of nociceptive withdrawal
responses caused by attention and emotional state that
may otherwise have led to variability in withdrawal
responses. A potential disadvantage of studying with-
drawal reflexes in anaesthetized animals is the poten-
tial for variability in the depth of anaesthesia between
animals, which would inevitably affect the MWT
(Grimby et al., 1966; Schouenborg and Kalliomaki,
1990; Boissonade and Matthews, 1993). This was con-
trolled for in the present study by standardizing depth
of anaesthesia as much as possible between animals by
starting at a relatively high anaesthetic depth and
decreasing the infusion rate of alfaxalone (and allow-
ing time for stabilization) until an EMG response was
observed to a standardized ramped mechanical pinch
(up to 120 g/mm2). Furthermore, data were compared
within animals over time in a repeated measures
design in which all post-drug time points were com-
pared with its pre-drug response.
The same experimenter induced the model and
carried out the experiment, and was thus not blinded
to the group or drug administered. This may be a
potential limitation of the study; however, because an
objective outcome measure was utilized, the non-
blinded nature of the experiment was unlikely to con-
found data. One rat in the UVB/HR (+MK-801) group
did not have evidence of secondary hyperalgesia pre-
drug administration, which could be attributed to
mechanical testing outside the boundary of secondary
hyperalgesia. We did not map the area of secondary
hyperalgesia prior to the experiment, which is a
potential study limitation. However, it is difficult to
behaviourally map the area of secondary hyperalgesia
with any precision in an animal model. Other poten-
tial explanations for the failure to display secondary
hyperalgesia may be due to stress, or adverse reactions
to the anaesthetic or surgical preparation.
With any pain model, repeatability of the charac-
teristics of the model is important. Following this
study, we have utilized the UVB/HR model in other
experiments with aims outside the scope of this
paper and have consistently demonstrated secondary
hyperalgesia.
5. Conclusion
A lower mechanical withdrawal threshold in UVB/HR
compared with SHAM-treated rats in the secondary
area confirms the development of central sensitization
in the model, supported by attenuation of the
observed secondary hyperalgesia by intrathecal
MK-801 in the UVB/HR group only. An important
feature of animal chronic inflammatory pain models is
reliability in induction of detectable secondary hyper-
algesia, which we have confirmed using a different
methodology to others. These studies further validate
the use of the UVB/HR model as a translational model
of inflammatory pain, which may have utility in
future pre-clinical rodent and human experimental
analgesic drug development studies, and help limit
drug redundancy between the pre-clinical and clinical
interface.
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